Bailard’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bailard’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90,200	Closed	-$167K	–	808
2023 Q1	$167K	Buy	+90,200	New	+$112K	0.01%	670
2022 Q1	–	Sell	-31,952	Closed	-$267K	–	827
2021 Q4	$267K	Hold	31,952	–	–	0.01%	572
2021 Q3	$237K	Hold	31,952	–	–	0.01%	623
2021 Q2	$217K	Buy	31,952 +15,400	+93%	+$128K	0.01%	652
2021 Q1	$170K	Buy	16,552 +1,000	+6%	+$11K	0.01%	674
2020 Q4	$109K	Buy	15,552 +900	+6%	+$7K	0.01%	616
2020 Q3	$120K	Hold	14,652	–	–	0.01%	528
2020 Q2	$101K	Hold	14,652	–	–	0.01%	487
2020 Q1	$70K	Hold	14,652	–	–	0.01%	442
2019 Q4	$128K	Sell	14,652 -8,148	-36%	-$44K	0.01%	523
2019 Q3	$76K	Hold	22,800	–	–	﹤0.01%	522
2019 Q2	$113K	Buy	22,800 +8,000	+54%	+$42.5K	0.01%	527
2019 Q1	$92K	Buy	+14,800	New	+$71.5K	0.01%	531

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bailard's JNCE Position: Q2 2023 in Review

Bailard sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 90,200 shares — an estimated $167K sold.

Bailard first reported a position in JNCE in Q1 2019 and held it in 13 quarters. The position peaked at $267K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Bailard reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bailard sold 90,200 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $167K.
Bailard first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
Bailard's Jounce Therapeutics, Inc. Common Stock position peaked at $267K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Bailard's 13F filing for Q2 2023, filed 20 Jul 2023.